Torrent Pharma Q3 PAT seen up 16% at Rs 130 crore

MUMBAI: Torrent Pharmaceuticals is likely to report a net profit of Rs 130 crore for the quarter ended December 2013, up 16 per cent, against the figure of Rs 112 crore in the corresponding quarter last fiscal year, according to an ET Now poll.

The company’s net sales in December 2013 quarter are seen at Rs 950 crore, up 23 per cent, as compared to Rs 769 crore in the year-ago period.

EBITDA is seen at Rs 191 crore, up 19 per cent, from Rs 161 crore; while margins are seen growing 20.1 per cent versus 20.9 per cent.

Analysts are of the view that exports and developed markets will lead growth for the company.

They see a 10-12 per cent growth for domestic markets. Cymbalta is expected add to overseas revenues, they say.

Revenues from the US are seen at 25-27 per cent of the total revenues; and those from Brazil at 10 per cent.